Needham Maintains Buy on NextCure, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has maintained a Buy rating on NextCure (NASDAQ:NXTC) and has also maintained a price target of $4 for the company's stock.
March 21, 2024 | 6:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum reaffirmed a Buy rating on NextCure, with a consistent price target of $4, indicating a positive outlook on the stock.
The reaffirmation of a Buy rating and a steady price target by a reputable analyst suggests a strong belief in the company's potential for growth or recovery. This endorsement could positively influence investor sentiment and potentially lead to an increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100